Germany's Evotec Q1 revenue falls on prior-year one-off

Evotec SE

06/05/2026 06:45

Overview

Germany drug discovery firm's Q1 revenue declined yr/yr due to prior-year one-off license payment

Adjusted Group EBITDA for Q1 turned negative, impacted by one-off effects and FX headwinds

Company confirmed full-year 2026 guidance; Horizon transformation expected to yield benefits later in yr

Outlook

Evotec confirms 2026 group revenue guidance of €700-780 mln

Company maintains 2026 adjusted group EBITDA guidance of €0-40 mln

Evotec expects operational improvements to become more visible in H2 2026

Result Drivers

ABSENCE OF ONE-OFF LICENSE PAYMENT - Co said Q1 revenue and profit declined due to lack of prior-year Sandoz license sale

REORGANIZATION COSTS - Q1 results included €75 mln in reorganization costs related to Horizon transformation

FOREIGN EXCHANGE HEADWINDS - Co said negative FX effects further impacted Q1 adjusted EBITDA

Company press release: ID:nEQ6SxkVRa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Gross Margin
-1%
Q1 Gross Profit
-EUR 1.57 mln
Q1 Operating Income
-EUR 121.4 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Evotec SE is €6.70, about 25.5% above its May 5 closing price of €5.34

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)